At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 668 enrolled
Drug / intervention
20-valent pneumococcal conjugate vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY UNBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY JAPANESE INFANTS
In Brief
A Phase 3 clinical trial evaluating 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine for Pneumococcal Disease. Completed, enrolled 668 participants across 38 sites.
Detailed Summary
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2020
Primary CompletionApr 2022
TodayJul 2026
First PostedAug 28, 2020
Enrollment StartSep 16, 2020
Primary CompletionApr 2, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.8 years ago
Interventions
20-valent pneumococcal conjugate vaccinebiological
20-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccinebiological
13-valent pneumococcal conjugate vaccine